Salubris Bio
  • About Us
    • Mission
    • Team
    • Our Focus
      • Pipeline
    • History
  • Research Focus
    • Cardio R&D
      • Heart Failure
      • Neuregulin
      • JK07
      • Clinical Trials
    • Oncology R&D
      • Oncology Overview
      • Focus Areas
    • Neurology R&D
  • Clinical Trials
  • News & Events
  • Careers
  • Contact
Select Page

Salubris Biotherapeutics Announces Updated Phase 1b Data Demonstrating that JK07, the First Investigational Antibody Fusion Protein for Heart Failure, Resulted in Clinically Meaningful Improvements in Ejection Fraction

by jonadmin | Sep 29, 2022 | Uncategorized

Salubris Biotherapeutics Announces New Pipeline Advancements and Appointment of Chief Medical Officer

by jonadmin | May 25, 2022 | Uncategorized

Salubris Biotherapeutics Announces $32 Million Financing to Advance Novel Complex Biologics for Cardiovascular, Oncology, and Neurodegenerative Diseases

by jonadmin | Mar 8, 2022 | Uncategorized

Recent Posts

  • Salubris Biotherapeutics Announces Updated Phase 1b Data Demonstrating that JK07, the First Investigational Antibody Fusion Protein for Heart Failure, Resulted in Clinically Meaningful Improvements in Ejection Fraction
  • Salubris Biotherapeutics Announces New Pipeline Advancements and Appointment of Chief Medical Officer
  • Salubris Biotherapeutics Announces $32 Million Financing to Advance Novel Complex Biologics for Cardiovascular, Oncology, and Neurodegenerative Diseases

Recent Comments

    Salubris Biotherapeutics, Inc © 2017-2023 | Privacy Policy | Terms & Conditions | site by Pierrot
    Maryland Tech Council | Better Together